Rezolute
1450 Infinite Drive
Louisville
Colorado
80027
United States
Tel: 303-222-2128
Website: https://www.rezolutebio.com/
Email: info@rezolutebio.com
42 articles about Rezolute
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences - Aug 03, 2021
8/3/2021
Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, announced that Nevan Charles Elam, CEO and Founder, will present at two upcoming virtual investment conferences.
-
Rezolute Added to Russell Microcap® Index
6/28/2021
Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, has been added to the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28.
-
Rezolute to Participate in Upcoming Virtual Healthcare Conferences - May 27, 2021
5/27/2021
Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to chronic glucose imbalance, announced that Nevan Charles Elam, CEO and Founder, will present at two upcoming virtual investment conferences.
-
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
5/17/2021
Rezolute, Inc., a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, announced that management will present at the Oppenheimer Rare and Orphan Disease Summit.
-
Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
5/17/2021
Rezolute, Inc., a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, announced its financial results for the fiscal third quarter ended March 31, 2021.
-
Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
5/4/2021
Results allow the Company to advance development, including planning for its multiple-ascending dose clinical study
-
Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
4/19/2021
Rezolute, Inc., a clinical stage biopharmaceutical company dedicated to advancing targeted therapies for rare and metabolic diseases with serious unmet needs, announced that it has entered into a $30 million debt financing agreement with investment affiliates managed by SLR Capital Partners.
-
Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
3/8/2021
Vlad Hogenhuis, M.D., MBA, and Nerissa C. Kreher, M.D., M.S., MBA, to join board of directors as Rezolute advances lead candidate, RZ358, in congenital hyperinsulinism through late-stage clinical trials
-
Rezolute Announces Change of Transfer Agent
12/28/2020
REDWOOD CITY, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq:RZLT), focused on advancing therapies for rare, metabolic and life-threatening diseases, announced today the appointment of IssuerDirect as the Company’s registrar and transfer agent and shareholder support provider. IssuerDirect will now be responsible for all transfers of Rezolute shares rather than VStock Transfer, LLC. Shareholders need take no action related to this transaction. About Rezolute, Inc. Rezol
-
Rezolute Announces Uplisting to the Nasdaq Capital MarketTrading expected to begin November 9, 2020
11/5/2020
Rezolute, Inc., a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced that the Company’s common shares have been approved for listing on the Nasdaq Capital Market.
-
XOMA Earns $1.9 Million Associated with Two Partner Developments
10/14/2020
In an unrelated development, apartnerinitiated Phase 2 development of an undisclosed asset, which triggers $0.5 million milestone payment to XOMA
-
Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
6/10/2020
Rezolute, Inc., announced that the company has received rare pediatric disease designation from the Food and Drug Administration for RZ358, a potential treatment for congenital hyperinsulinism that is currently being evaluated in a global Phase 2b study.
-
Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
5/14/2020
Rezolute, Inc., announced an update on the potential impact of the global COVID-19 pandemic on the Company’s clinical and business operations.
-
Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
2/10/2020
REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical trial of its lead candidate, RZ358, in patients with congenital hyperinsulinism (CHI). The Company has screened the first patient and expects to make significant enrollment progress to enable attainment of mid-study results over the coming year. “Congenital hyperinsulinism is the most common cau
-
Rezolute to Present at BIO CEO & Investor Conference 2020
1/27/2020
Rezolute, Inc.(“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical development in rare disease at the BIO CEO & Investor Conference 2020, to be held in New York, NY on February 10 – 11. CFO Dr. Keith Vendola, M.D., is scheduled to present on Monday, February 10 at 10 a.m. ET.
-
Clinical Catch-Up: December 16-20
12/23/2019
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look. -
Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
12/18/2019
Rezolute, Inc.(“Rezolute” or “the Company”) (OTCQB:RZLT) today announced top-line results from its Phase 1 trial of AB101, an ultra-long acting basal insulin for potential use in patients with type 1 and type 2 diabetes.
-
Sanofi: information concerning the total number of voting rights and shares, October 2019
11/25/2019
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers.